C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)
C4 Therapeutics' (CCCC) quarterly Preferred Stock Liabilities came in at $256.5 million in Q3 2020, up 133.21% year-on-year from $110.0 million in Q4 2019, and up 81.9% quarter-over-quarter from $141.0 million in Q2 2020.
C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
C4 Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $256.5 million for Q3 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 133.21% year-over-year to $256.5 million in Q3 2020; TTM through Sep 2020 was $256.5 million, a 133.21% increase from a year earlier, with the FY2019 full-year figure at $111.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $256.5 million in Q3 2020 per CCCC's latest filing, from $141.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $256.5 million in Q3 2020 and bottomed at $110.0 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 256.52 Mn |
| Jun 30, 2020 | 141.03 Mn |
| Dec 31, 2019 | 111.00 Mn |
| Sep 30, 2019 | 110.00 Mn |